A personalized, evidence-based approach to obesity therapy using clinical algorithms: semaglutide or tirzepatide
On June 26, 2025, a meeting of the expert working group was held in Moscow. The discussion focused on the personalized approach of tirzepatide («Tirzetta®») and semaglutide («Velgia Eco®») in patients with excess body weight, obesity, and type 2 diabetes. Following the meeting, the objective was set to develop a consensus-based algorithm for prescribing these drugs to ensure their effective use in Russian clinical practice.
Nutritional status with tirzepatide in obesity: A post hoc analysis of the SURMOUNT-1-4 randomized clinical trials
CONCLUSIONS: TEAEs and treatment discontinuations due to macronutrient malnutrition were uncommon in the SURMOUNT-1-4 trials of tirzepatide for obesity. Lack of routinely collected vitamin and mineral levels during the trials limited assessment of the impact of tirzepatide treatment on micronutrient status. Systematic assessment of nutritional status before and during OMM treatment would enhance future trials.
Beyond lifestyle modification: the role of GLP-1 receptor agonists in treating pediatric obesity
Childhood obesity is a global health crisis with limited effective therapies beyond lifestyle modification. This review examines the growing role of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in the management of pediatric obesity. Simultaneously, this study highlights the critical considerations for clinicians in administering these medications, including long-term safety, efficacy, potential adverse effects, and overall clinical utility. To enhance the effectiveness of GLP-1 RAs in…
Variable Effects of Glucagon Like Peptide-1 Receptor Agonists on Body Composition in Older Women
CONCLUSION: Clinicians should consider recommending individualized exercise programs and dietary strategies for older patients taking GLP-1 RAs. Routine assessment of body composition may help guide interventions and optimize clinical outcomes.
GLP-1s and the Super Bowl
The Super Bowl is once again getting the GLP-1 ad treatment.
Hims & Hers is back with another combative spot that calls out the disparities in healthcare experiences between the …
Big Pharma’s most valuable up-and-coming GLP-1s
Late-stage GLP-1 candidates from Eli Lilly, Novo Nordisk and Amgen have a combined net present value of $68 billion.
Lilly Axes Three Therapies Amid Pipeline-in-a-Product Push for GLP-1
One of the assets shelved by Eli Lilly is a gene therapy for dementia, which it obtained in its $1.04-billion acquisition of Prevail Therapeutics in late 2020.
A sneak peek of pharma’s Super Bowl ads: GLP-1s, tight ends, and more
What drug ads will air during Sunday’s Super Bowl? STATus Report host Alex Hogan and reporter at large Damian Garde have a rundown of what to expect.
Semaglutide improves cardiovascular health but price reductions are needed to make it cost-effective, study finds
Semaglutide, the active ingredient in the weight-loss medications Ozempic and Wegovy, offers substantial cardiovascular benefits for selected patients without diabetes who have established heart disease, but further price reductions are needed to make the therapy good value for money, according to a new analysis from researchers at Beth Israel Deaconess Medical Center (BIDMC).
Lilly Eyes Pipeline in a Product as GLP-1s Move Into I&I
In addition to claiming revenue of $19.3 billion for the fourth quarter, Eli Lilly executives offered a glimpse into their strategy to expand their GLP-1 franchise into the immunology and inflammation space, with trials currently underway in asthma, psoriatic arthritis, Crohn’s disease and ulcerative colitis.